Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Acta Neuropathol. 2014 Jan 3;127(5):621–632. doi: 10.1007/s00401-013-1236-0

Figure 2. Proposed models for CSF Apo-E effects in AD.

Figure 2

CSF Apo-E as a neuroprotective mechanism that fails in advanced disease stages (a) and CSF Apo-E levels as a neuroprotective mechanism that modulates disease progression (b).